About 6.4 million doses of the COVID-19 vaccine from Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) will ship to U.S. states in mid-December, as long as the vaccine soon receives an FDA EUA. There are also plans to quickly distribute vaccine from rival COVID-19 vaccine developer Moderna (NSDQ:MRNA), which could soon apply for an EUA, officials at the federal […]
Pfizer
HHS confirms involvement in presidential transition process
U.S. Health and Human Services Dept. Secretary Alex Azar confirmed that HHS is working with president-elect Joe Biden on a presidential transition. Speaking during a press briefing, Azar said HHS is in contact with the transition team after the General Services Administration formally recognized Biden as the president-elect, having previously sidestepped questions regarding the potential […]
Who would — and wouldn’t — line up for COVID-19 vaccines?
Once enough people receive effective vaccines against the novel coronavirus, experts say, the end of the pandemic may be in sight. But a new poll of older adults — one of the highest-priority groups for vaccination — suggests an uphill climb lies ahead to reach that goal. In all, 58% of adults aged 50 to […]
5 takeaways from the latest White House Coronavirus Task Force meeting
The White House Coronavirus Task Force promised a swift rollout of COVID-19 vaccines — but one of a number of takeaways from its first briefing since July. The briefing yesterday gave the task force a chance to once again urge Americans to heed COVID-19 guidance while also providing an update on vaccines and therapeutics. The […]
BREAKING: Pfizer, BioNTech submit FDA EUA request for COVID-19 vaccine
Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) announced that they will submit a request today with FDA for an EUA of their mRNA vaccine candidate, BNT162b2, against SARS-CoV-2. If all goes as planned, the companies predict that high-risk populations in the U.S. could start receiving the vaccine by mid- to late-December. Vaccine distribution could start within […]
Why the COVID-19 vaccine market won’t be ‘winner take all’
There are a dozen Phase 3 COVID-19 vaccine candidates with more than 50 in either Phase 1 or Phase 2 trials. But the fact that Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have vaccine candidates with efficacy greater than 90% could ultimately narrow the playing field. “Efficacy matters, but I don’t think [Pfizer’s and Moderna’s efficacy rate of] greater […]
Moderna and Pfizer COVID-19 vaccines set a high bar for competitors
Moderna (NSDQ:MRNA) is now the second company to release positive preliminary results from a Phase 3 trial of a COVID-19 vaccine candidate — and it appears to be more good news. Last week, Pfizer (NYSE:PFE) announced that early data suggested its BNT162 mRNA-based vaccine was more than 90% effective at reducing symptomatic COVID-19 infections. Today, […]
COVID-19 vaccine rally sees testing companies’ stocks dip
News of Pfizer and BioNTech’s COVID-19 vaccine candidate performing well has caused markets to rally this week. The two companies are collaborating on a vaccine candidate that has proven in early clinical data to be approximately 90% effective, and the news helped to propel MassDevice’s MedTech 100 Index to a new record high yesterday. However, […]
7 things to know about COVID-19 vaccines
Enthusiasm surrounding COVID-19 vaccines is on the upswing after Pfizer announced preliminary data suggesting its vaccine could be 90% effective at preventing COVID-19 infections. The Bay Area Council hosted a webinar yesterday to provide more information about coronavirus vaccines. Here are seven considerations to keep in mind now that the prospect of a widely deployed COVID-19 […]
Pfizer claims its COVID-19 vaccine could be 90% effective
Pfizer (NYSE:PFE) has announced its vaccine candidate promises to be 90% effective in protecting against COVID-19 infections. The announcement included the interim analysis results of its Phase 3 trial. Pfizer had earlier suggested that it would announce those results in late October. The promising data clears the way for Pfizer to apply for emergency-use authorization from FDA […]
MedTech 100 roundup: Stocks show no signs of slowing down
The medtech industry hit further highs in the market last week and the stocks show no sign of stopping their ascent now. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 97.62 (Nov. 6), marking a 7.3% leap from the 91.01 points registered at the […]
